All stock lists
CVS HEALTH Corp (New York Stock Exchange:CVS)
US · Delayed Price · Currency is USD
Also listed: CVS.DE, 0HRS.LHealthcare · Medical - Healthcare Plans
83.85+2.52 (+3.10%)
Market cap
$107B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 21, 1973
Website
Insider Score
85/ 100
CVS Insider Score
Bullish1 qualifying trade · 1 insider · $2.00M bought in the last 90 days
CVS analyst forecast
CVS analyst consensus
Moderate Buy6 ratings
Buy 6 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CVS 12-month price target
$109.56+32.4% upsideaverage of 9 firms
$126.00High
$95.00Low
CVS ratings mix, last 12 months
Buy Hold Sell
Best analysts covering CVS
- Wells Fargo100%success rate · +30.3% avg return · 4 calls
- Leerink Partners100%success rate · +22.8% avg return · 1 call
- Argus Research100%success rate · +29.3% avg return · 1 call
- Baird100%success rate · +50.2% avg return · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CVS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Jefferies | — | $103.00 | +28.8% | — | 2026-11-04 | |
| Raymond James | — | $120.00 | +31.3% | — | 2026-11-04 | |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-10-12 |
| — | UBS | Buy | — | — | Reiterated | 2026-09-03 |
| — | Argus Research | Buy | — | — | Reiterated | 2026-08-19 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-12 |
| UBS | Buy | $126.00 | +27.1% | Reiterated | 2026-08-06 | |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-06 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-08-06 |
| Robert W. Baird | — | $107.00 | +10.4% | — | 2026-08-06 | |
| — | UBS | Buy | — | — | Reiterated | 2026-07-24 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-07-14 |
| Truist Financial | — | $118.00 | +11.4% | — | 2026-07-14 | |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-13 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-07-07 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-06-23 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-06-08 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-06-04 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-06-01 |
| Piper Sandler | — | $113.00 | +24.2% | — | 2026-06-01 | |
| Barclays | Overweight | $106.00 | +15.7% | Reiterated | 2026-05-26 | |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-05-20 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-05-14 |
| — | Bernstein | Outperform | — | — | Reiterated | 2026-05-13 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-05-12 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-05-11 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-05-08 |
| Barclays | Overweight | $101.00 | +16.3% | Reiterated | 2026-05-07 | |
| — | UBS | Buy | — | — | Reiterated | 2026-05-07 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-05-07 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-05-07 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-05-07 |
| — | Baird | Outperform | — | — | Reiterated | 2026-04-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-03-31 |
| — | Bernstein | Outperform | — | — | Upgraded | 2026-03-12 |
| Leerink Partners | — | $98.00 | +23.3% | — | 2026-03-05 | |
| — | Argus Research | Buy | — | — | Reiterated | 2026-01-28 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-01-27 |
| — | Bernstein | Market Perform | — | — | Reiterated | 2026-01-06 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-12-17 |
| — | Bernstein | Market Perform | — | — | Reiterated | 2025-12-12 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-12-10 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-12-10 |
| UBS | Buy | $97.00 | +24.0% | Reiterated | 2025-12-10 | |
| Mizuho | Outperform | $95.00 | +20.2% | Reiterated | 2025-12-10 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-12-10 |
| — | Baird | Outperform | — | — | Reiterated | 2025-12-10 |
| Piper Sandler | Overweight | $101.00 | +29.1% | Reiterated | 2025-12-10 | |
| — | Bernstein | Market Perform | — | — | Reiterated | 2025-12-05 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-13 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-11-03 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-10-30 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2025-10-30 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-10-30 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-10-30 |
| — | UBS | Buy | — | — | Reiterated | 2025-10-24 |
CVS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-10 | 1.00 | 1.09 | $103.70B | $105.69B |
| 2026-05-06 | 2.18 | 2.57 | $94.99B | $100.43B |
| 2026-08-05 | 1.85 | 2.58 | $100.03B | $106.10B |
| 2026-11-04 | 1.65 | 2.09 | $104.69B | $108.40B |
| 2027-02-09Upcoming | 1.26 | — | $106.89B | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.